ramatroban 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
thromboxane A2-receptor antagonists; antithrombotic agents 2354 116649-85-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ramatroban
  • baynas
thromboxane A2 receptor antagonist; BAY u 3405 & 3406 are enantiomers of each other
  • Molecular weight: 416.47
  • Formula: C21H21FN2O4S
  • CLOGP: 3.97
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 88.40
  • ALOGS: -4.26
  • ROTB: 5

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.2 acidic
pKa2 9.56 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Thromboxane A2 receptor GPCR INVERSE AGONIST Ki 9.24 CHEMBL KEGG DRUG
Prostaglandin D2 receptor 2 GPCR Ki 8.37 CHEMBL
Prostaglandin D2 receptor GPCR Ki 4.96 CHEMBL
Prostaglandin D2 receptor 2 GPCR ANTAGONIST IC50 7.30 IUPHAR
Prostaglandin D2 receptor 2 GPCR ANTAGONIST Ki 7.30 IUPHAR

External reference:

IDSource
D01128 KEGG_DRUG
C0753318 UMLSCUI
CHEBI:32087 CHEBI
A8X PDB_CHEM_ID
CHEMBL361812 ChEMBL_ID
DB13036 DRUGBANK_ID
C063119 MESH_SUPPLEMENTAL_RECORD_UI
123879 PUBCHEM_CID
1911 IUPHAR_LIGAND_ID
7273 INN_ID
P1ALI72U6C UNII

Pharmaceutical products:

None